Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Part Of Brain That Taps Into Our Memory Banks Pinpointed, Johns Hopkins University Study

Hopkins Neuroscientists Pinpoint Part Of Brain That Taps Into Our Memory Banks Two parts of hippocampus work together to determine whether stimulus is completely new or related to something familiar You see a man at the grocery store. Is that the guy you went to college with or just someone who looks like him? One […]

Read More »

Bay Area’s Raptor Beefs Up Portfolio With $453 Million Deal for Quinsair

Raptor Pharmaceutical Corp. (RPTP) is beefing up its rare disease portfolio with the $453 million acquisition of Quinsair, first inhaled fluoroquinolone approved for the management of chronic pulmonary infections in adults with cystic fibrosis, the company announced this morning. Quinsair is a twice-per-day treatment that contains levofloxacin, an antimicrobial active against a wide range of […]

Read More »

Novartis buys remaining rights to GSK treatment for up to $1 billion

Novartis has agreed to buy all remaining rights to Ofatumumab from Britain’s GlaxoSmithKline for up to $1 billion, boosting the Swiss drugmaker’s stable of multiple sclerosis (MS) treatments.   Basel-based Novartis had previously acquired the rights to Ofatumumab for oncology indications, but it is currently being developed for relapsing remitting multiple sclerosis and other auto-immune […]

Read More »

N.Y.C. Legionnaires’ Outbreak Over, City Says

New York City’s Legionnaires’ disease outbreak is officially over, health officials said on Thursday, confirming that the Opera House Hotel in the South Bronx was its source. The outbreak, which officials called the worst for Legionnaires’ in the city’s history, killed 12 people and sickened 128 since early July. No new illnesses have been identified […]

Read More »

Samsung Makes First Foray Into U.S. Stock Market

SEOUL—Samsung will make its first entry into U.S. stock markets with an anticipated $1 billion listing of its biotechnology affiliate, according to people familiar with the matter, marking a major step in the South Korean conglomerate’s foray into a new industry outside its better-known electronics business. The listing of Samsung Bioepis Co. on the Nasdaq […]

Read More »

The FDA Is Basically Approving Everything. Here’s The Data To Prove It

Remember when the FDA rejected drugs? We just got treated to a whole lot of drama this week as to whether Addyi, a drug to boost women’s libidos, would be approved. But based on the data, that approval was probably a foregone conclusion. As recently as 2008, companies filing applications to sell never-before-marketed drugs, which […]

Read More »

Birth control pills may offer lasting endometrial cancer protection

Women who use oral contraceptives during their reproductive years may gain long-term protection against endometrial cancer, a review of previous research suggests. Researchers analyzed 36 studies including more than 140,000 women from around the world. They found that every five years of taking birth control pills was linked to a 24 percent reduction in the […]

Read More »

Extra virgin olive oil linked to lower blood sugar and cholesterol

Compared to other kinds of fat, extra virgin olive oil may have healthier effects on levels of blood sugar and bad cholesterol after meals, according to an Italian study. That may explain why a traditional Mediterranean diet rich in olive oil is linked to lower risk of cardiovascular disease, researchers say. “Lowering (post-meal) blood glucose […]

Read More »

60 Degrees Pharmaceuticals to Begin Phase II Clinical Trials in Dengue Fever Patients

WASHINGTON, Aug. 20, 2015 /PRNewswire/ — 60 Degrees Pharmaceuticals, (60P), a company focused on development of therapeutics for tropical diseases, and Singapore General Hospital (SGH) announced today that the Hospital has received a grant from Singapore’s National Medical Research Council to support a Phase II clinical trial among dengue fever patients. Dengue fever, a painful, debilitating and […]

Read More »

Lilly, Boehringer diabetes drug cuts heart attack, stroke risk in trial

A new diabetes pill from Eli Lilly and Co and Boehringer Ingelheim cut risk of heart attack, stroke and death in a closely watched study, the first glucose-lowering drug to show such protective results in a large cardiovascular trial, the drugmakers said on Thursday. Besides burnishing the image of the year-old drug, Jardiance, the results […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom